Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates. "Xencor designs proteins that enable potential first-in-class and best-in- class medicines for patients, and we are building on momentum from 2025, when we presented. ...